Looking for research-grade compounds?
Every peptide that shows up in a research catalog — BPC-157, TB-500, GHK-Cu, or any of the hundreds of compounds laboratories order for in-vitro work — began as an idea on paper: a specific sequence of amino acids. Turning that sequence into a physical vial of material is a manufacturing problem chemists have been refining for over a century. So how are peptides made? Today, the overwhelming answer is solid-phase peptide synthesis, or SPPS — a method that builds the chain one amino acid at a time while it hangs from a tiny plastic bead. This guide walks through how that process works, why it beat every alternative, where it struggles, and what it means for researchers reading a COA. If you need a refresher on what a peptide is first, start there. Strictly research-use-only (RUO) framing throughout — this is chemistry, not usage guidance.
A peptide bond is just an amide linkage between the carboxyl group of one amino acid and the amino group of the next, with a molecule of water released. In principle, you could mix amino acids and let them join. In practice, it’s chaos: every amino acid carries both an amino group and a carboxyl group, plus reactive side chains, so an unprotected mixture polymerizes randomly into a useless mess. Emil Fischer, who coined the word “peptide” in the early 1900s, recognized the core problem immediately: you need protecting groups — chemical masks that block every reactive site except the one you want to react — and you must add them, couple, and remove them in the right order, purifying after every step.
The pioneers did exactly that in solution. Vincent du Vigneaud’s 1953 synthesis of oxytocin (work that earned the 1955 Nobel Prize in Chemistry) and Panayotis Katsoyannis’s 1963 total synthesis of insulin — the first chemical synthesis of a protein — were heroic multi-year efforts precisely because each coupling step demanded isolation and purification of the intermediate. A 30-residue peptide built that way could consume a researcher’s entire career.
Robert Bruce Merrifield, working at Rockefeller University, published the fix in 1963: anchor the growing chain to an insoluble solid support — a polystyrene resin bead — and do all the chemistry on the bead. Because the peptide never leaves the solid phase, you never have to purify intermediates. Instead, you drive each reaction to completion with a large excess of reagents and simply wash the leftovers away. Filter, rinse, repeat. The idea was so powerful that it earned Merrifield the 1984 Nobel Prize in Chemistry, and by the mid-1960s he had already built the first automated peptide synthesizer around it. More than six decades later, SPPS remains the dominant way research peptides are made, from milligram bench scale to multi-kilogram manufacturing.
The standard direction is C-terminus to N-terminus: the first amino acid is anchored by its carboxyl group, and each new residue is added to the free amino end. One full cycle adds exactly one residue, and the cycle repeats until the sequence is complete.
The C-terminal amino acid is covalently attached to the resin through a linker molecule, and the linker’s chemistry decides what the finished peptide’s C-terminus looks like. A Wang resin releases the peptide as a free carboxylic acid; a Rink amide resin releases it as a C-terminal amide; a 2-chlorotrityl resin allows cleavage under very mild acid so side-chain protecting groups stay on — useful when making protected fragments for later assembly. The incoming amino acid’s alpha-amino group wears a temporary protecting group (usually Fmoc), and its side chain wears semi-permanent protection, so nothing reacts except where intended.
The Fmoc group is stripped with a mild base — typically 20% piperidine in dimethylformamide (DMF) — exposing a free amino group ready for the next coupling. (In the older Boc chemistry, this step uses trifluoroacetic acid instead.) Fmoc removal is conveniently monitored by UV absorbance, since the liberated protecting group absorbs strongly — automated synthesizers use that signal to confirm each deprotection worked.
The next Fmoc-protected amino acid is added along with a coupling reagent that activates its carboxyl group, making it reactive enough to form the peptide bond. The classics are carbodiimides like DCC and DIC; modern workhorses include uronium salts such as HBTU and HATU, plus additives like Oxyma that suppress racemization — the scrambling of an amino acid’s stereochemistry that would otherwise create mirror-image impurities. A 3- to 5-fold excess of reagents pushes the coupling toward completion in minutes to hours.
The resin is washed to remove excess reagents, and any chains that failed to couple are “capped” — typically with acetic anhydride — so they can’t keep growing and become hard-to-remove deletion impurities. Completion is verified with colorimetric tests like the Kaiser (ninhydrin) test, which turns deep blue in the presence of free amines, or by quantifying the Fmoc chromophore released in the following deprotection.
Once the full sequence is assembled, strong acid — usually a trifluoroacetic acid (TFA) cocktail with scavengers like water, triisopropylsilane, and ethanedithiol — simultaneously releases the peptide from the resin and strips off all the acid-labile side-chain protecting groups. The scavengers matter: they trap the highly reactive carbocations liberated from the protecting groups before those fragments can reattach to sensitive residues like tryptophan, cysteine, or methionine. The crude peptide is then precipitated, typically in cold ether.
Crude SPPS product is a mixture: the target peptide plus truncated, capped, and side-reaction impurities. Preparative reversed-phase HPLC separates the full-length product, which is then lyophilized (freeze-dried) into the familiar white powder. Identity is confirmed by mass spectrometry and purity by analytical HPLC — the same two pillars you’ll find on any legitimate certificate of analysis, which is why knowing how to read a COA tells you so much about how well a peptide was made.
| Fmoc/tBu (modern standard) | Boc/Bzl (classic) | |
|---|---|---|
| N-terminal deprotection | Mild base (piperidine) | Acid (TFA) every cycle |
| Final cleavage | TFA (strong but manageable) | Anhydrous HF (hazardous, specialized equipment) |
| Orthogonality | Base-labile N-protection + acid-labile side chains = fully orthogonal | Less orthogonal; harsher throughout |
| Typical use today | Nearly all research and most commercial peptides | Niche cases (e.g., thioesters for native chemical ligation) |
The Fmoc strategy, developed by Atherton and Sheppard in the late 1970s, won because it is gentler, safer, and gives cleaner crude products. Boc chemistry survives where its specific cleavage behavior is needed.
SPPS is not magic; it has well-known failure modes. The math is unforgiving: even 99% coupling efficiency per step gives only about 60% overall yield for a 50-residue chain, and real couplings are rarely all 99%. Beyond roughly 50 amino acids, stepwise SPPS becomes impractical. Some sequences are “difficult” — hydrophobic stretches that aggregate into beta-sheets on the resin, physically blocking further coupling. The field has developed workarounds: pseudoproline dipeptide building blocks that disrupt aggregation (standard in GLP-1 analogue synthesis), microwave-assisted SPPS that accelerates hindered couplings, and backbone-protecting strategies that keep the growing chain solvated.
Cyclic peptides add another layer: after linear assembly, the ends must be joined — head-to-tail cyclization on the resin or in solution — or disulfide bridges must be formed by controlled oxidation, with protecting-group strategies that pair the right cysteines. Getting cyclization wrong is a classic source of isomeric impurities.
For longer chains, biology beats chemistry. Recombinant expression — inserting the peptide’s genetic code into E. coli or yeast and harvesting the product from fermentation — handles sequences SPPS can’t touch, including full proteins. The reference semaglutide product, a 31-amino-acid peptide, is manufactured exactly this way: recombinant DNA technology in Saccharomyces cerevisiae yeast produces the precursor chain, which is then chemically modified with the fatty-acid side chain that extends its half-life, per the European Medicines Agency’s product description. A June 2026 PLOS ONE study even demonstrated gram-per-liter production of a semaglutide intermediate in engineered E. coli, a sign of how actively this hybrid bio-plus-chemistry route is being optimized. Native chemical ligation (Dawson and Kent, 1994) offers a third path: synthesize short fragments by SPPS and stitch them together through a chemoselective reaction at cysteine junctions, enabling synthetic proteins well past the stepwise length limit.
SPPS has a dirty secret: it guzzles solvent. DMF, the workhorse solvent for coupling and washing, is effective but reprotoxic, and a single synthesis can consume liters of it per gram of product. That footprint is now under serious attack. In November 2025, CPC Scientific published a DMF recycling strategy for large-scale SPPS that substantially cuts solvent consumption and cost. Euroapi has reported replacing DMF with a greener dimethyl sulfoxide/ethyl acetate mixture, monitored in real time by Raman spectroscopy as a process analytical tool. And a 2026 Green Chemistry paper demonstrated solvent-less amide coupling using resonant acoustic mixing — no bulk solvent, fewer reagent equivalents, and a five-fold reduction in process mass intensity, validated on bioactive peptides and scaled tenfold. Greener synthesis isn’t just environmental virtue; it directly lowers the cost of high-purity material.
Now that you know how peptides are made, it changes how you evaluate material. Purity claims on a supplier page are only as good as the analytical data behind them — an HPLC chromatogram and a mass spectrum on the COA are the direct descendants of the purification and verification steps above. Synthesis also explains practical realities: why longer peptides cost more (the yield math), why “crude” material is cheaper but unsuitable for serious work, and why lyophilized powder stored cold and dry is the stable endpoint of the whole process — see our peptide storage best practices for the details. Browse the research peptide catalog with that lens, and check third-party verification on our COA testing page. And when catalog copy leans on slang like “peps” or “peppers,” remember the RUO framing that governs all of this: these are laboratory reagents, full stop.
How long does it take to synthesize a peptide?
On an automated synthesizer, each deprotection–coupling–wash cycle takes roughly 10–30 minutes, so a 15-residue peptide can be assembled in a day or two. Cleavage, purification, and lyophilization add several more days — purification is usually the bottleneck, not assembly.
Why are longer peptides so much more expensive?
Yield decays multiplicatively with each coupling, so a 40-mer costs far more than twice a 20-mer: more starting material, more failed chains to separate, and more difficult purification. This is also why recombinant routes take over for long sequences.
What’s the difference between crude and purified peptide?
Crude material comes straight off the resin after cleavage: the target plus deletion sequences, capped fragments, and side products. Purified (HPLC) material has those removed. For any quantitative or comparative research, crude material’s impurity profile makes results unreliable.
Do research peptides contain residual TFA?
Usually, yes, in trace amounts — TFA is the cleavage acid, and peptides are typically isolated as TFA salts, which can matter for cell-based assays sensitive to counterions. Some suppliers offer acetate or hydrochloride salt exchange for that reason.
Can any amino acid sequence be synthesized?
In principle, most sequences under about 50 residues are accessible, but aggregation-prone or sterically hindered sequences may need specialized building blocks or conditions. Sequences with multiple disulfides or complex cyclization require custom folding protocols.
Related in the Apex shop: Research peptides at Apex Bio — supplied strictly for laboratory research use.
This article is an educational overview of peptide synthesis chemistry for laboratory researchers. All compounds discussed are intended strictly for in-vitro research use only (RUO) — not for human or veterinary use, not as therapeutics, and not as dietary supplements. Nothing here constitutes manufacturing, dosing, or usage instructions. Researchers are responsible for complying with all applicable regulations and institutional policies.
Selank peptide research starts with an unusual origin story. Most research peptides begin as fragments of a hormone or growth
Retatrutide Peptide Research: The Triple Agonist, TRIUMPH Trials and FDA Status Retatrutide peptide research is where incretin science stopped adding
Sermorelin Peptide Research: GHRH(1-29), GH Pulses and FDA History Sermorelin peptide research occupies an unusual place in the peptide literature:
